First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH)
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Alemtuzumab (Primary) ; Ciclosporin; Methylprednisolone; Prednisolone
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 20 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 20 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 01 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.